Patent ID: 7297330

Claim:
A method for inducing an anti-tumor response in a human patient suffering from a tumor, which method comprises administering to the patient in the following order: (a) on the first day of treatment, a first composition comprising from about 2×10 5 to 2.5×10 6 of at least one of autologous tumor cells or autologous tumor cell equivalents free from any adjuvant; (b) four to seven days after initiation of the treatment, cyclophosphamide; and (c) at least one week after initiation of the treatment, a second composition comprising an adjuvant and from about 2×10 5 to about 1×10 7 of at least one of autologous tumor cells or tumor cell equivalents, wherein said tumor cells or tumor cell equivalents are conjugated to hapten, wherein the hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, N-iodoacetyl-N′-(5-sulfonic 1-naphthyl) ethylene diamine, trinitrobenzenesulfonic acid, fluorescein isothiocyanate, arsenic acid benzene isothiocyanate, sulfanilic acid, arsanilic acid, dinitrobenzene-S-mustard and combinations thereof, wherein said method results in at least one of an anti-tumor response, therapeutic regression of a tumor or prevention of tumor progression.